SEC Form 4 · accession 0000950138-18-000053
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Patruno Sheehy
Officer — Sr. VP & Chief Compliance Off.
Period of report
Mar 1, 2017
Accepted (ET)
Jan 5, 2018 · 7:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Mar 1, 2017 | A | 582 | $0.00 | A | 4,835 | D | |
| Ordinary Shares | Jan 3, 2018 | F | 460 | $23.51 | D | 4,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F2 | $51.55 | Mar 1, 2017 | A | 1,635 | A | Mar 1, 2018 | Mar 1, 2027 | Ordinary Shares | 1,635 | 1,635 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning March 1, 2018.
- F2The options vest in four equal annual installments beginning March 1, 2018.